Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06578585
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Interventional Randomized Double-blind Placebo-controlled Trial Investigating the Safety and Tolerability of Lu AG09222 When Coadministered With Ubrogepant in Participants With Migraine
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant This includes looking for any new or worsening medical issues the participants have with the treatment During the trial participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None